drugset / Trial / NCT02314377
Bevacizumab Therapy for Brain Arteriovenous Malformation
NaSingle-groupOpen-labelTreatment
Summary
Bevacizumab Therapy for brain arteriovenous malformation that is not amenable to surgical intervention.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-12-01
- Completion
- 2019-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |